We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+1.1%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$800M
AUM Growth
-$196M
(-20%)
Cap. Flow
-$191M
Cap. Flow
% of AUM
-23.93%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
76
New
18
Increased
11
Reduced
22
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$44.5M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$28.7M |
| 3 |
Agilent Technologies
A
|
+$25.7M |
| 4 |
Amgen
AMGN
|
+$18.3M |
| 5 |
DexCom
DXCM
|
+$15.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$73M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$47.1M |
| 3 |
Natera
NTRA
|
+$39.7M |
| 4 |
Boston Scientific
BSX
|
+$34.1M |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$27.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.88% |
| 2 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KZR
26
DELISTED
Kezar Life Sciences
KZR
| $13.8M | 1.73% |
160,765
+39,777
| +33% | +$3.86M |
|
27
CVS Health
CVS
$122B
| $12.5M | 1.56% |
+131,150
| New | +$13M |
|
28
McKesson
MCK
$101B
| $11.9M | 1.49% |
35,040
| – | – |
|
29
Abbott
ABT
$187B
| $9.58M | 1.2% |
98,970
-100,330
| -50% | -$10.7M |
|
30
Molina Healthcare
MOH
$10.3B
| $9.08M | 1.14% |
+27,540
| New | +$8.87M |
|
|
HOLX
31
DELISTED
Hologic
HOLX
| $8.86M | 1.11% |
137,330
-264,780
| -66% | -$18.3M |
|
|
SGEN
32
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.85M | 0.98% |
57,340
-45,720
| -44% | -$7.45M |
|
33
Rocket Pharmaceuticals
RCKT
$395M
| $7.1M | 0.89% |
+445,140
| New | +$6.95M |
|
|
BPMC
34
DELISTED
Blueprint Medicines
BPMC
| $6.89M | 0.86% |
+104,600
| New | +$6.72M |
|
35
Inspire Medical Systems
INSP
$1.74B
| $6.78M | 0.85% |
+38,240
| New | +$7.68M |
|
36
Alkermes
ALKS
$8.25B
| $6.78M | 0.85% |
+303,500
| New | +$7.89M |
|
|
IMGN
37
DELISTED
Immunogen Inc
IMGN
| $6.21M | 0.78% |
1,300,000
+800,000
| +160% | +$4.22M |
|
|
SWAV
38
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $5.48M | 0.69% |
+19,720
| New | +$5.01M |
|
|
MRUS
39
DELISTED
Merus
MRUS
| $5.47M | 0.68% |
272,890
+153,690
| +129% | +$3.67M |
|
|
KDNY
40
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.25M | 0.66% |
+266,830
| New | +$5.35M |
|
41
Dentsply Sirona
XRAY
$2.43B
| $4.49M | 0.56% |
+158,200
| New | +$5.41M |
|
42
Geron
GERN
$949M
| $4.46M | 0.56% |
1,904,234
+904,234
| +90% | +$2.02M |
|
|
AFMD
43
DELISTED
Affimed
AFMD
| $3.55M | 0.44% |
172,193
| – | – |
|
|
CANO
44
DELISTED
Cano Health, Inc.
CANO
| $3.43M | 0.43% |
+3,956
| New | +$2.48M |
|
45
NeoGenomics
NEO
$2.13B
| $3.37M | 0.42% |
+391,110
| New | +$3.88M |
|
|
NVRO
46
DELISTED
NEVRO CORP.
NVRO
| $3.15M | 0.39% |
+67,600
| New | +$3.14M |
|
|
BLUE
47
DELISTED
bluebird bio
BLUE
| $2.88M | 0.36% |
+22,750
| New | +$2.57M |
|
|
48
Natera
NTRA
$46.2B
| $2.85M | 0.36% |
65,130
-833,290
| -93% | -$39.7M |
|
49
Neurocrine Biosciences
NBIX
$16.6B
| $2.31M | 0.29% |
+21,720
| New | +$2.2M |
|
50
Hyperfine
HYPR
$94.2M
| $2.23M | 0.28% |
2,749,400
| – | – |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2022 Portfolio in Review
As of Q3 2022, HealthCor Management held 76 positions worth $800M, down 20% from $995M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
HealthCor Management withdrew a net $191M in Q3 2022, closing 17 positions and reducing 22 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $27.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier, followed by Financials.
Against the trend, HealthCor Management opened a new position in AbbVie worth $41.6M.
- HealthCor Management's largest Q3 2022 buy was AbbVie: 310,250 shares worth $41.6M.
- HealthCor Management added most to Agilent Technologies in Q3 2022, an estimated $25.7M increase.
- HealthCor Management's biggest Q3 2022 reduction was Biogen, cutting an estimated $73M.
- HealthCor Management fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $27.2M.
- HealthCor Management's ten largest holdings make up 46% of its $800M portfolio in Q3 2022.
- HealthCor Management opened 18 new positions and closed 17 in Q3 2022.
- HealthCor Management's portfolio value fell 20% quarter-over-quarter to $800M.
Based on HealthCor Management's 13F filing for Q3 2022, filed 14 Nov 2022.